Erratum: Changes in Bone Mineral Density after Initiation of Antiretroviral Treatment with Tenofovir Disoproxil Fumarate/Emtricitabine plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir (J Infect Dis. (2015) 212: 8 (1241-1249) DOI: 10.1093/infdis/jiv194)

Todd T. Brown, Carlee Moser, Judith S. Currier, Heather J. Ribaudo, Jennifer Rothenberg, Theodoros Kelesidis, Otto Yang, Michael P. Dubé, Robert L. Murphy, James H. Stein, Grace A. McComsey

Research output: Contribution to journalComment/debate

Abstract

In "Changes in Bone Mineral Density afer Antiretroviral Initiation with Tenofovir Disoproxil Fumarate-Emtricitabine plus Atazanavir-Ritonavir, Darunavir-Ritonavir, or Raltegravir [J Infect Dis. 2015 Oct 15;212(8):1241 9.] by Brown et al. there are three errors noted by the authors: Lines 176 180 Corrected sentence should read: Te following monocyte cell phenotypes were characterized and expressed as percentages: classical phenotype (CD14+CD16-), intermediate phenotype (CD14+CD16+), non-classical phenotype (CD14dimCD16+). CD4+ and CD8+ T cells with activated (HLA-DR+CD38+), senescent (CD28-CD57+) or senescent and exhausted (CD28- CD57+PD1+) phenotypes were assessed. (Table Presented).

Original languageEnglish (US)
Pages (from-to)2083-2084
Number of pages2
JournalJournal of Infectious Diseases
Volume221
Issue number12
DOIs
StatePublished - Jun 11 2020

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Erratum: Changes in Bone Mineral Density after Initiation of Antiretroviral Treatment with Tenofovir Disoproxil Fumarate/Emtricitabine plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir (J Infect Dis. (2015) 212: 8 (1241-1249) DOI: 10.1093/infdis/jiv194)'. Together they form a unique fingerprint.

  • Cite this